Results 151 to 160 of about 753,800 (311)

Real‐World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real‐World Analysis

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Talquetamab is a GPRC5D × CD3 bispecific antibody approved for relapsed/refractory multiple myeloma (RRMM). This is the first real‐world study to comprehensively report muco‐cutaneous toxicities, infections, and efficacy of talquetamab in 151 patients across five countries with the longest follow‐up reported enabling better efficacy and ...
Murali Janakiram   +94 more
wiley   +1 more source

Publisher Correction: Microbiota-induced T cell plasticity enables immune-mediated tumour control. [PDF]

open access: yesNature
Najar TA   +6 more
europepmc   +1 more source

Working on a Lathe in the Carpentry Department of the New York Trade School

open access: yes, 2015
A student or teacher at the New York Trade School is shown working on a lathe in the Carpentry Department. Black and white photograph credited to the New York City Works Progress Administration.https://academicworks.cuny.edu/ny_arch_nyts_img/1023 ...
W.P.A., New York Trade School
core  

Exploring the Burden on Patients Living With and Receiving Treatment for Immune Thrombocytopenia (ITP): Patient and Physician Perceptions From the ITP World Impact Survey (I‐WISh) 2.0

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Limited data exist on how patients and physicians perceive immune thrombocytopenia (ITP) symptoms and treatment‐related burden. I‐WISh (ITP World Impact Survey) 2.0 surveyed 1018 patients and 431 physicians in 15 countries to characterize the impact of ITP and its treatments on patients.
Nichola Cooper   +17 more
wiley   +1 more source

A novel hierarchical framework elucidating regional differences in α-synuclein and tau co-pathology in military veterans with parkinsonism. [PDF]

open access: yesJ Neuropathol Exp Neurol
Flores Almazan VG   +16 more
europepmc   +1 more source

New York Law School Magazine, Vol. 26, No. 2

open access: yes, 2007
Features: Extreme Makeover: New York Law School Edition Wired for Success: The Law Student of the Future New on the Market: The Center for Real Estate Studieshttps://digitalcommons.nyls.edu/alum_mag/1014/thumbnail ...
New York Law School
core  

Correction of Ineffective Erythropoiesis and Normalization of Iron Homeostasis After Exagamglogene Autotemcel in Transfusion‐Dependent β‐Thalassemia

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Exagamglogene autotemcel (exa‐cel) is a one‐time, ex vivo, CRISPR‐Cas9 gene edited cell therapy approved for patients with transfusion dependent β‐thalassemia (TDT) aged 12–35 years. In a Phase 3 study (CLIMB THAL‐111), exa‐cel treatment resulted in reactivation of fetal hemoglobin and increases in total hemoglobin, leading to transfusion ...
Sujit Sheth   +25 more
wiley   +1 more source

Demonstration of Closed Circuit TV by filming Wiliam C. H. Meyer in an Automotive classroom at the New York Trade School

open access: yes, 2015
Depiction of closed circuit TV students at the New York Trade School filming a voltage regulator check performed by William C. H. Meyer. Original caption reads, Closed-circuit TV takes a class at the New York Trade School into the Automotive Shop where ...
New York Trade School
core  

Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Hypomethylating agents (HMA) and allogeneic hematopoietic stem cell transplantation (alloHSCT) have both demonstrated remissions in VEXAS; however, comparative data is lacking. We conducted a multicenter, retrospective analysis of 66 patients diagnosed with VEXAS syndrome treated with HMA (n = 35) or alloHSCT (n = 31). Baseline characteristics
Saubia Fathima   +48 more
wiley   +1 more source

Home - About - Disclaimer - Privacy